The evolving landscape of oncolytic virus immunotherapy: combinatorial strategies and novel engineering approaches

Area of Science:

• Oncology
• Immunotherapy
• Virology

Background:

• Oncolytic viruses (OVs) are engineered or naturally occurring viruses that selectively infect and lyse cancer cells.
• OVs stimulate both innate and adaptive immune responses against tumors, offering a dual mechanism of action.
• Current OV therapies face challenges related to delivery, tumor penetration, and overcoming the immunosuppressive tumor microenvironment.

Purpose of the Study:

• To review recent technological advancements in oncolytic virus (OV) therapy.
• To explore combination strategies to enhance the efficacy of OV immunotherapy.
• To identify challenges and future directions for developing more effective OV-based cancer treatments.

Main Methods:

• Review of current literature on oncolytic virus technology and immunotherapy.
• Analysis of strategies for engineering OVs to express therapeutic genes and modulate the tumor microenvironment.
• Assessment of synergistic combinations of OVs with other immunotherapies, including immune checkpoint inhibitors and cell therapy.

Main Results:

• OVs induce direct tumor cell killing (oncolysis) and release tumor-associated antigens, priming the immune system.
• Engineered OVs can be designed to express therapeutic payloads, enhance immune cell infiltration, and counteract tumor-induced immunosuppression.
• Combining OVs with immune checkpoint inhibitors and cell therapies shows potential for improved antitumor responses and durable remission.

Conclusions:

• Oncolytic virus immunotherapy is a rapidly evolving field with significant potential for cancer treatment.
• Technological innovations and strategic combination therapies are crucial for overcoming current limitations and maximizing OV efficacy.
• Further research into OV delivery, targeting, and combination strategies is essential for their successful clinical translation.